Carsten Boess

CIK: 0001277495

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

RCKT

ROCKET PHARMACEUTICALS, INC.

Director

RNA

Atrium Therapeutics, Inc.

Director

RNAM

Avidity Biosciences, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

RCKT
ROCKET PHARMACEUTICALS, INC.
Jun 18, 2026
Award(A)
Direct
22.9K shares-
RNA
Atrium Therapeutics, Inc.
Feb 27, 2026
Award(A)
Stock Option (Right to Buy)
Direct
20K shares-
RNAM
Avidity Biosciences, Inc.
Feb 27, 2026
Disposition(D)
Direct
6.7K shares-
RCKT
ROCKET PHARMACEUTICALS, INC.
Jun 18, 2025
Award(A)
Direct
30K shares-
RNA
Avidity Biosciences, Inc.
Jun 10, 2025
Award(A)
Direct
6.7K shares-

		Type	Shares	Price		Ownership
Jun 18, 2026	RCKT ROCKET PHARMACEUTICALS, INC.	Award(A)	22,862	-	$0	Direct
Feb 27, 2026	RNA Atrium Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	20,000	-	-	Direct
Feb 27, 2026	RNAM Avidity Biosciences, Inc.	Disposition(D)	6,692	-	$0	Direct
Jun 18, 2025	RCKT ROCKET PHARMACEUTICALS, INC.	Award(A)	30,000	-	-	Direct
Jun 10, 2025	RNA Avidity Biosciences, Inc.	Award(A)	6,692	-	-	Direct

1-5 of 5 transactions

About BOESS CARSTEN

BOESS CARSTEN (SEC CIK 0001277495) files insider reports with the SEC as Director of ROCKET PHARMACEUTICALS, INC. (RCKT), Director of Atrium Therapeutics, Inc. (RNA) and Director of Avidity Biosciences, Inc. (RNAM).

Signal8 holds 6 ownership filings by BOESS CARSTEN (1 Form 3, 5 Form 4), filed between Jun 12, 2025 and Jul 6, 2026. Those filings report 5 transactions, from Jun 10, 2025 to Jun 18, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on BOESS CARSTEN's filings is in CRANBURY, NJ.

Recent filings by BOESS CARSTEN

Jun 18, 2026: Grant or award of RCKT shares (Form 4, code A).
Feb 27, 2026: Grant or award of RNA derivative securities (Form 4, code A).
Feb 27, 2026: Disposition to issuer transaction of RNAM shares (Form 4, code D).
Jun 18, 2025: Grant or award of RCKT shares (Form 4, code A).
Jun 10, 2025: Grant or award of RNA shares (Form 4, code A).

Other insiders filing for ROCKET PHARMACEUTICALS, INC. (RCKT)

Wilson Martin, General Counsel
Shah Gaurav, CEO
Stevens Christopher James, Chief Operating Officer
Chaudhuri Sarbani
SOUTHWELL DAVID P, Director
Manhede Joseph, Principal Accounting Officer

How to read Form 4 transaction codes